BASKING RIDGE, N.J., Jan. 15 /PRNewswire/ -- Regado Biosciences, Inc., announced today the appointment of Steven L. Zelenkofske, D.O., F.A.C.C. to the position of Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer, effective immediately. He will report to David J. Mazzo, Ph.D., the Company's President and Chief Executive Officer.
Dr. Mazzo stated, "Steven has led clinical programs for more than 15 development-stage and commercialized cardiovascular products during his pharmaceutical career and has extensive experience as a principal investigator on a number of important trials in cardiovascular medicine. His track record will be critical as Regado advances its lead therapeutic candidate, the REG1 Anticoagulation System, through late-stage clinical development." Regado recently completed enrollment in a Phase IIa clinical study (REVERSAL-PCI) of REG1 in patients undergoing elective percutaneous coronary intervention.
Dr. Zelenkofske's addition completes the new executive team at Regado. He joins recently appointed Senior Vice President of Regulatory Affairs and Quality Assurance, Dr. Alex Giaquinto and Ellen McDonald, the recently announced Senior Vice President of Business Operations and Chief Business Officer.
Most recently, Dr. Zelenkofske served as Vice President, Cardiovascular/Thrombosis Medical Unit - US at Sanofi-Aventis Pharmaceuticals and, prior to this, as Vice President of Clinical Sciences and Chief Patient Safety Officer for Boston Scientific Corporation's Cardiac Rhythm Management (CRM) Group. At both companies, Dr. Zelenkofske led the development and implementation of cardiovascular pre- and post-market clinical strategy. Prior to this, he was a senior director with Novartis Pharmaceuticals, where he held positions of increasing responsibility within its cardiovascular division, attaining the position of Senior Medical Director, US Clinical Development, Hyperten
|SOURCE Regado Biosciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved